We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+44.98%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$874M
AUM Growth
+$263M
Cap. Flow
+$99.1M
Cap. Flow %
11.34%
Top 10 Hldgs %
49.85%
Holding
55
New
15
Increased
6
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$53.3M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$45.7M
3
LQDA icon
Liquidia Corp
LQDA
+$34.2M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$21.6M
5
URGN icon
UroGen Pharma
URGN
+$17.5M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$33.1M
2
ZLAB icon
Zai Lab
ZLAB
+$25.3M
3
CMPX icon
Compass Therapeutics
CMPX
+$17.8M
4
ALKS icon
Alkermes
ALKS
+$16.5M
5
VERA icon
Vera Therapeutics
VERA
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTX icon
26
Context Therapeutics
CNTX
$35.3M
$15.7M 1.8%
10,679,391
-4,026,491
-27% -$4.7M
ARQT icon
27
Arcutis Biotherapeutics
ARQT
$2.99B
$15.4M 1.77%
+531,200
New +$13.6M
VTYX
28
DELISTED
Ventyx Biosciences
VTYX
$14.8M 1.69%
+1,639,061
New +$12.2M
ORIC icon
29
Oric Pharmaceuticals
ORIC
$1.37B
$14.7M 1.68%
1,798,717
+69,339
+4% +$798K
BLTE
30
Belite Bio
BLTE
$6.11B
$14M 1.61%
+87,760
New +$10.4M
RAPT
31
DELISTED
RAPT Therapeutics
RAPT
$13.5M 1.54%
+397,906
New +$12.4M
CLYM
32
Climb Bio
CLYM
$837M
$10.7M 1.22%
+2,671,480
New +$6.42M
ABVX
33
Abivax
ABVX
$9.89B
$7.59M 0.87%
+56,316
New +$6.14M
RCKT icon
34
Rocket Pharmaceuticals
RCKT
$424M
$5.57M 0.64%
1,586,076
-2,317,305
-59% -$7.93M
MAZE
35
Maze Therapeutics
MAZE
$1.52B
$3.36M 0.38%
+81,145
New +$2.79M
EVMN
36
Evommune Inc
EVMN
$480M
$1.93M 0.22%
+113,022
New +$2.12M
SRPT icon
37
Sarepta Therapeutics
SRPT
$2.2B
$1.51M 0.17%
70,000
-630,000
-90% -$13.3M
HOWL icon
38
Werewolf Therapeutics
HOWL
$45.8M
$884K 0.1%
1,393,557
-1,015,253
-42% -$1.23M
AKBA icon
39
Akebia Therapeutics
AKBA
$243M
– –
-2,889,125
Closed -$7.89M
ALKS icon
40
Alkermes
ALKS
$7.95B
– –
-549,262
Closed -$16.5M
ASMB icon
41
Assembly Biosciences
ASMB
$694M
– –
-39,665
Closed -$1.02M
CMPX icon
42
Compass Therapeutics
CMPX
$432M
– –
-5,075,970
Closed -$17.8M
DSGN icon
43
Design Therapeutics
DSGN
$946M
– –
-555,187
Closed -$4.18M
JANX icon
44
Janux Therapeutics
JANX
$1.1B
– –
-614,282
Closed -$15M
RARE icon
45
Ultragenyx Pharmaceutical
RARE
$2.52B
– –
-395,700
Closed -$11.9M
RNAM
46
DELISTED
Avidity Biosciences
RNAM
– –
-760,022
Closed -$33.1M
RNAC icon
47
Cartesian Therapeutics
RNAC
$290M
– –
-380,000
Closed -$3.88M
RPTX
48
DELISTED
Repare Therapeutics
RPTX
– –
-819,924
Closed -$1.44M
SLDB icon
49
Solid Biosciences
SLDB
$1.05B
– –
-1,634,569
Closed -$10.1M
SLNO
50
DELISTED
Soleno Therapeutics
SLNO
– –
-150,000
Closed -$10.1M
1
2
3

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2025 Portfolio in Review

As of Q4 2025, MPM BioImpact held 55 positions worth $874M, up 43% from $611M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

MPM BioImpact deployed $99.1M of net new capital in Q4 2025, opening 15 new positions and adding to 6 existing holdings. Its largest new stake was uniQure: 1,381,628 shares worth $33.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $13.3M trimmed.

  • MPM BioImpact's largest Q4 2025 buy was uniQure: 1,381,628 shares worth $33.1M.
  • MPM BioImpact added most to Liquidia Corp in Q4 2025, an estimated $34.2M increase.
  • MPM BioImpact's biggest Q4 2025 reduction was Sarepta Therapeutics, cutting an estimated $13.3M.
  • MPM BioImpact fully exited Avidity Biosciences in Q4 2025, selling an estimated $33.1M.
  • MPM BioImpact's ten largest holdings make up 50% of its $874M portfolio in Q4 2025.
  • MPM BioImpact opened 15 new positions and closed 17 in Q4 2025.
  • MPM BioImpact's portfolio value rose 43% quarter-over-quarter to $874M.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.